Skip to main content

Volume 9 Supplement 1

Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference

Proceedings

Edited by Diana W Shineman and Howard M Fillit

The conference and the publication of these proceedings were supported by conference grant U13-AG031125 from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the National Institutes of Health's Office of Rare Diseases. Other sponsors: CoMentis, Eli Lilly and Company, sanofi-aventis, Biogen Idec and The Michael J. Fox Foundation for Parkinson's Research

Drug Discovery for Neurodegeneration Conference. Go to conference site.

Washington, DC, USA2-3 February 2009

  1. The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening has increased the attrition rate of weak drug candidates early in the drug-discovery process, and decreased t...

    Authors: Katya Tsaioun, Michel Bottlaender and Aloise Mabondzo
    Citation: BMC Neurology 2009 9(Suppl 1):S1

Annual Journal Metrics

  • 2022 Citation Impact
    2.6 - 2-year Impact Factor
    2.9 - 5-year Impact Factor
    1.092 - SNIP (Source Normalized Impact per Paper)
    0.771 - SJR (SCImago Journal Rank)

    2023 Speed
    26 days submission to first editorial decision for all manuscripts (Median)
    154 days submission to accept (Median)

    2023 Usage 
    3,186,031 downloads
    2,601 Altmetric mentions 

Sign up for article alerts and news from this journal